Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2005-11-08
2005-11-08
Housel, James (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C424S184100, C424S231100, C424S192100, C424S093100, C424S093200, C536S023400, C536S023700, C536S023720, C536S023500, C435S069100, C435S069300, C435S091100, C435S091400
Reexamination Certificate
active
06962709
ABSTRACT:
The invention provides HSV antigens that are useful for the prevention and treatment of HSV infection. Disclosed herein are epitopes confirmed to be recognized by T-cells derived from herpetic lesions. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection.
REFERENCES:
patent: 4859587 (1989-08-01), Roizman
patent: 5632992 (1997-05-01), Nesburn et al.
patent: 5714152 (1998-02-01), Burke et al.
patent: WO 92/02251 (1992-02-01), None
patent: WO 95/16779 (1995-06-01), None
patent: WO 97/05265 (1997-02-01), None
patent: WO 98/20016 (1998-05-01), None
patent: WO 098/20016 (1998-05-01), None
Cox et al. vaccine 1997, vol. 15, No. 3, pp. 248-256.
Roux et al. Molecular Endocrinology 1996, vol. 10, pp. 1214-1226.
Rueda et al. Virology 1994, vol. 198, pp. 65-662.
Leib et al. J. Virol. 1989, vol. 63, No. 2, pp. 756-768.
Kawaguchi et al. J. Virol. 1997, vol. 71, No. 10, pp. 7328-7336.
Aurelian et al. Cancer Cells, 1989, vol. 7, pp. 187-191.
Everett et al. (a) Virol. 1993, vol. 197, pp. 751-756.
Everett et al. (b) J.Nuceic acids Research 1991, vol. 19, No. 22, pp. 6155-6161.
Yao et al. J. Virol. 1994, vol. 68, No. 12, pp. 8158-8168.
M.A. Tigges et al.(1992) Human CD8+Herpes Simplex Virus-Specific Cytotoxic T-Lymphocyte Clones Recognize Diverse Virion Protein Antigens,Journal of Virology,66(3):1622-1634.
C.M. Posavad et al. (1996) High Frequency of CD8+Cytotoxic T-Lymphocyte Precursors Specific for Herpes Simplex Viruses in Persons with Genital Herpes,Journal of Virology70(11):8165-8168.
D.M. Koelle et al. (1998) Clearance of HSV-2 from Recurrent Genital Lesions Correlates with Infiltration of HSV-Specific Cytotoxic T Lymphocytes,The Journal of Clinical Investigation101(7):1500-1508.
D.M. Koelle et al. (1997) Preferrential Presentation of Herpes Simplex Virus T-Cell Antigen by HLA DQA1*0501/DQB1*0201 in Comparison to HLA DQA1*0201/DQB1*0201,Human Immunology53(2):195-205.
S. Reichstetter et al. (1999) MHC-Peptide Ligand Interactions Establish a Functional Threshold for Antigen-Specific T Cell Recognition,Human Immunology60(7):608-618.
W.W. Kwok et al. (1999) Peptide Binding Affinity and pH Variation Establish Functional Thresholds for Activation of HLA-DQ-Restricted T Cell Recognition,Human Immunology60(7):619-626.
D.M. Koelle et al. (1994) Direct Recovery of Herpes Simplex Virus (HSV)-Specific T Lymphocyte Clones from Recurrent Genital HSV-2 Lesions,The Journal of Infectious Diseases169:956-61.
D.M. Koelle et al. (1994) Antigenic Specificities of Human CD+T-Cell Clones Recovered from Recurrent Genital Herpes Simplex Virus Type 2 Lesions,Journal of Virology68(5):2803-2810.
A. Dolan et al. (1998) The Genome Sequence of Herpes Simplex Virus Type 2,Journal of Virology72(3):2010-2021.
G. Elliott and P. O'Hare (1997) Intercellular Trafficking and Protein Delivery by a Herpesvirus Structural Protein,Cell88:223-233.
E. De Plaen et al. (1997) Cloning of Genes Coding for Antigens Recognized by Cytolytic T Lymphocytes,Immunology Methods Manual692-718.
Tatman, J.D. et al., “Assembly of Herpes Simplex Virus Type 1 Using a Panel of Recombinant Baculoviruses,”Journal of General Virology,(1994), 75, 1101-1113.
D.M. Koelle, (1995) The Roles of T Lymphocytes in Host Responses to Herpes Simplex Virus,Herpes,2:83-88.
B. Roizman et al., “Herpes Simplex Viruses and Their Replication”, In: Fundamental Virology, 2ndEdition, ed. Fields et al, Raven Press, New York, pp. 849-895.
Manickan, E. et al.,J. Virol,(1995) 69(8) pp. 4711-4716.
O. Bjornberg, et al., “dUTPhase from Herpes Simplex Virus Type 1; Purification from infected Green Monkey Kidney (Vero) Cells and from an OverproducingEscherichia coliStrain”, (1993), vol. 4, pp. 149-159.Protein Expression and Purification.
M. Williams et al., “Characterization of a Herpes Simplex Virus Type 2 Deoxyuridine Triphosphate Nucleotidohydrolase and Mapping of a Gene Conferring Type Specificity for the Enzyme”, (1987)Virology,vol. 156, pp. 282-292.
M. Williams, “Deoxyuridine Triphosphate Nucleotidohydrolase Induced by Herpes Simplex Virus Type 1”,Journal of Biological Chemistry(1984) vol. 259(16), pp. 10080-10084.
D.M. Koelle et al., “Recognition of Herpes Simplex Virus Type 2 Tegument Proteins by CD4 T Cells Infiltrating Human Genital Herpes Lesions”,Journal of Virology,(1998) vol. 72(9), pp. 7476-7483.
Chen Hongbo
Corey Lawrence
Fling Steven P.
Hosken Nancy Ann
Koelle David M.
Gates & Cooper LLP
Housel James
Li Bao Qun
University of Washington, Fred Hutchinson Cancer Research Center
LandOfFree
Immunologically significant herpes simplex virus antigens... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunologically significant herpes simplex virus antigens..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunologically significant herpes simplex virus antigens... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3499340